Navigation Links
EndoChoice(R) Receives 510K Clearance for its BONASTENT(R) Esophageal and Biliary Stent Platforms
Date:4/29/2010

ALPHARETTA, Ga., April 29 /PRNewswire/ -- EndoChoice, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its BONASTENT® Fully Covered Esophageal Stent for the treatment of malignant esophageal obstructions, and its BONASTENT Uncovered Biliary Stent for the treatment of malignant biliary obstructions.

With over 8,000 placements worldwide, the BONASTENT platform has provided physicians treating malignant strictures in the GI tract increased clinical performance attributed to its revolutionary "Hook & Cross" wire geometry. The BONASTENT's proprietary Hook & Cross wire geometry provides segmental compression, reducing stent migration typically experienced with other metal stent platforms.  

"I have been very pleased with my placements of the BONASTENT," said Peter Stevens, M.D., Director of Endoscopy at New York Presbyterian Hospital/Columbia University Medical Center in New York. "It has performed beautifully and I look forward to incorporating future EndoChoice BONASTENT platforms into my practice."

"This revolutionary line of metal stents will make a tremendous impact improving the quality of life for the tens of thousands of patients suffering from GI cancers," said Mark Gilreath, Founder and CEO of EndoChoice.  "We are pleased to have such a successful product launch in the United States and Europe.  Patients can now benefit from the unique feature of segmental compression, only offered in the BONASTENT platform technology."

The BONASTENT platform will be available for hands-on demonstration at the 2010 Digestive Disease Week conference, which is being held in New Orleans on May 2nd through 5th.

BONASTENT Esophageal

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100429/NY95943 )

About EndoChoice, Inc.

EndoChoice designs, manufactures and markets innovative solutions for professionals in gastrointestinal endoscopy worldwide.  Its diverse portfolio of high-quality equipment, devices, supplies and services uniquely positions EndoChoice as a leading resource for GI professionals.  The company strives to exceed its customers' expectations through its superior products, exemplary customer care, knowledgeable sales force, and easy online ordering.  For more information, visit www.EndoChoice.com.


'/>"/>
SOURCE EndoChoice, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EndoChoice(R) Launches CEU Program on Proper Endoscope Reprocessing and a Line of Flexible Endoscope Reprocessing Products
2. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
3. Mylan Receives Approval for Generic Version of Flomax(R)
4. BioMedix Receives Clinical Approval for TRAKnet Software
5. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
6. Flexuspine Receives FDA Conditional Approval to Begin a Feasibility Study of Its FSU (Functional Spinal Unit) Total Spine Arthroplasty System in the United States
7. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
8. ATS Medical Receives Approval to Commercialize the ATS Simulus Annuloplasty Products in Canada
9. Actavis Receives Approval of Alprazolam ODT in the U.S.
10. Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
11. Watson Receives FDA Approval for Generic Cardizem(R) LA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):